UBS Maintains Neutral on 10x Genomics, Raises Price Target to $68

Benzinga Newsdesk www.benzinga.com Neutral 60.5%

Neg 0% Neu 60.5% Pos 0%

UBS analyst Dan Leonard maintains 10x Genomics (NASDAQ:TXG) with a Neutral and raises the price target from $20 to $68.

Comments

No comments yet. Be the first!